Novo Nordisk is cutting the out-of-pocket prices of its popular weight-loss drug Wegovy and diabetes drug Ozempic for some consumers. Current customers who pay for the drugs out of pocket — without ...

Novo Nordisk has reported the mixed midphase results behind its push to enter a heart disease market served by Alnylam Pharmaceuticals, BridgeBio and Pfizer. The phase 2 trial compared two doses of ...

(Bloomberg) --Lars Rebien Sorensen is back as chairman of Novo Nordisk A/S following a shareholder meeting that exposed the depth of rivalry between the Danish drugmaker and US arch nemesis Pfizer Inc ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Within the next two weeks ...

GLP-1 weight loss drugs are still far from cheap, but some of the prices keep dropping. Novo Nordisk is now offering people who pay out of pocket a steep discount for select doses of Ozempic and ...

Novo Nordisk has jumped the gun on US price reductions for its blockbuster diabetes and weight-loss drug semaglutide, cutting the monthly price to $349, earlier than expected, for people willing to ...

Novo has experienced a prolonged sell.off over the last months, declining more than 65% from all-time highs. Why some kind of pessimism is justified, the current market cap is way to low considering ...

Novo Holdings sells 155 million Convatec shares at 5.1% discount Sale marks Novo's exit from Convatec Convatec shares fall as much as 4.3% Shares in Convatec fell as much as 4.3% to 228.8 pence per ...

Nov 13 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab and Eli Lilly (LLY.N), opens new tab denied weight-loss drug partnership with Mangoceuticals (MGRX.O), opens new tab on Thursday, hours after ...

Facing increased competition in the weight loss market and intense pressure from President Donald Trump, Novo Nordisk announced Monday that it is lowering prices for its blockbuster obesity and ...

Signed, sealed and delivered, Metsera is finally Pfizer’s. Pfizer has completed its acquisition of the obesity biotech, capping a whirlwind two weeks in which rival pharma Novo Nordisk attempted to ...

Days after joining its fellow GLP-1 giant Eli Lilly in coming to agreements with the Trump administration to slash the costs of their uber popular weight loss meds in the U.S., Novo Nordisk has pulled ...